T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis

To determine if MRD (minimal residual disease) can be found in the blood (only) as opposed to bone marrow in children with ALL (acute lymphoblastic leukemia).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Leukemia, Lymphocytic, Acute Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, Lymphoid Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Precursor Cell Lymphoblastic Leukemia-Lymphoma

Age range

Up to 18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Stanford University School of Medicine

Stanford, California, 94305, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Children with newly diagnosed T-cell ALL

Treatment and study plan

Bone Marrow Aspiration

Procedure

peripheral blood sampling

Procedure

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Official study title

T-cell MRD Evaluation Using Flow Cytometric Analysis

Important dates

Study start: 2002
Primary completion: 2007
Study completion: 2007
First posted: Mar 2, 2010
Registry last updated: Mar 2, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed